Evidence map›Paper›PMID 38020289›Full record

ArticleOncology letters2023

Assessment of the expression of microRNAs‑221‑3p, ‑146a‑5p, ‑16‑5p and BCL2 in oncocytic carcinoma of the breast: A case report.

Yumiko Koi, Yuki Yamamoto, Saori Fukunaga, Keiko Kajitani, Masahiro Ohara, Yutaka Daimaru, Hidetoshi Tahara, Ryuichiro Tamada

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yumiko KoiDepartment of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
Yuki YamamotoDepartment of Cellular and Molecular Biology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8553, Japan.
Saori FukunagaDepartment of Cellular and Molecular Biology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8553, Japan.
Keiko KajitaniDepartment of Breast Surgery, Japan Agricultural Co-operatives Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.
Masahiro OharaDepartment of Breast Surgery, Japan Agricultural Co-operatives Hiroshima General Hospital, Hatsukaichi, Hiroshima 738-8503, Japan.
Yutaka DaimaruSection of Pathological Research and Laboratory, Japan Agricultural Co-operatives Hiroshima General Hospital, Hiroshima 738-8503, Japan.
Hidetoshi TaharaDepartment of Cellular and Molecular Biology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima 734-8553, Japan.
Ryuichiro TamadaDepartment of Surgery, Nishiki Hospital, Yamaguchi 741-0061, Japan.
Hiroshima General Hospital · JPHiroshima University · JPNational Hospital Organization Kyushu Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncocytic carcinoma of the breast is rare and its molecular profiles remain poorly understood. MicroRNAs (miRNAs/miRs) have been identified as contributors to carcinogenesis at the post-transcriptional level; thus, an aberrant expression of miRNAs has attracted attention as a potential biomarker of numerous diseases, including cancer. The present study reports the case of a 76-year-old woman diagnosed with oncocytic carcinoma of the breast. Considering the distinctive feature of oncocytic carcinoma of the breast, which is the presence of granular eosinophilic cytoplasm containing numerous mitochondria, the present study hypothesized that the expression of mitochondria-related miRNAs could be altered in oncocytic carcinomas. Aberrant expression levels of the miRNAs previously reported as mitochondria-related miRNAs, such as miR-221-3p, -146a-5p and -16-5p, were revealed in tissue from specimens of oncocytic carcinoma of the breast, compared with that of a more typical type of invasive ductal carcinoma of the breast. The present study highlights the changes in miRNA expression in oncocytic carcinoma of the breast, suggesting its potential as a biomarker for diagnosis.

Indexed as

BCL2breast cancermicroRNAoncocytic carcinoma

Identifiers

PMID38020289
PMCPMC10655050
OpenAlexW4388074394

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.